Investigational drug · Phase 2
SP-420
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Beta Thalassemia Major Anemia, Myelodysplastic Syndrome.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "SP-420"
First trial start
2023
Sep 4, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SP-420", any sponsor or status.
Conditions studied
As listed on its trial records.
- Beta Thalassemia Major Anemia
- Myelodysplastic Syndrome
Approved drugs for the same conditions: Myelodysplastic syndromes · Anemia · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "SP-420" as an intervention, largest first.
Pharmacosmos A/SIndustry
NCT05693909 · 90 participants (planned) · Start Sep 4, 2023 · Primary completion Oct 2027
Drug: SP-420 · For: Beta Thalassemia Major Anemia; Myelodysplastic Syndrome
Sites: Copenhagen, Denmark
Sideris PharmaceuticalsIndustry
NCT02274233 · 24 participants · Start Oct 2014 · Primary completion Sep 2015
Drug: SP-420 · For: Iron Overload; Beta-Thalassemia
Sites: Boston, Massachusetts; New York, New York; Philadelphia, Pennsylvania · 7 sites in all
The University of Texas Health Science Center at San AntonioAcademic, hospital or other
NCT04741542 · 2 participants · Start Mar 9, 2021 · Primary completion Jan 10, 2024
Drug: SP-420 · For: Iron Overload
Sites: San Antonio, Texas
Abfero Pharmaceuticals, IncIndustry
NCT03801889 · 0 participants · Start Aug 2020 · Primary completion Sep 2022
Drug: SP-420 · For: Iron Overload; Beta-Thalassemia
Sites: Toronto, Canada; Beirut, Lebanon; Bangkok, Thailand · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia.
Taher AT, Saliba AN, Kuo KH, et al. · Am J Hematol 2017
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.